TCL Archive Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light December 5, 2014
TCL Archive FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended July 28, 1989
TCL Archive NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification April 10, 1981
TCL Archive FDA, NCI, CMS Announce Biomarker Initiative; First Project To Validate FDG-PET As Predictor Of Tumor Response In Non-Hodgkin’s Lymphoma. February 17, 2006
